The first patient was dosed at The University of Texas MD Anderson Cancer Center in Houston, US. Credit: Nguyễn Hiệp on Unsplash.

Ideaya Biosciences has dosed the first patient in the Phase l trial examining IDE161 (NCT 05787587) to treat patients having tumours with homologous recombination deficiency (HRD).

The patient was dosed at The University of Texas MD Anderson Cancer Center in Houston, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties along with preliminary efficacy of IDE161 as monotherapy in the targeted patients.

Its clinical protocol includes dose escalation in solid tumours with HRD. 

Based on the selection of an expansion dose, IDEAYA expects to increase the cohorts of patients with HRD tumours in breast cancer, ovarian cancer and other solid tumours. 

See Also:

The breast cancer cohort of the trial will concentrate on estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (Her2-) tumours with HRD, which account for around 10% to 14% of breast cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics associate professor Dr Timothy Yap is a leading principal investigator of the trial.

IDE161 is a potent, selective, small-molecule PARG inhibitor.

IDEAYA Biosciences chief medical officer Dr Darrin Beaupre said: “We believe IDE161 may be impactful for ER+ / Her2- breast cancer patients with HRD, as well as for patients having ovarian cancer and other solid tumours with HRD, for whom current treatment options are limited.

“Based on its preclinical tolerability profile, IDE161 may also be suitable for evaluation with several distinct classes of combination agents, providing multiple paths to demonstrate patient benefit in these populations.”